{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T09:06:10Z","timestamp":1784019970583,"version":"3.55.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Tianjin Health Research Project","award":["TJWJ2024QN018"],"award-info":[{"award-number":["TJWJ2024QN018"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-026-06597-6","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T08:25:48Z","timestamp":1784017548000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative safety profiles of enzalutamide, olaparib, and lutetium Lu-177 vipivotide tetraxetan in patients with prostate cancer: a real-world disproportionality analysis of the FAERS database"],"prefix":"10.1007","volume":"44","author":[{"given":"Ruitao","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taipeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianpeng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanjie","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"key":"6597_CR1","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1080\/13696998.2023.2299179","volume":"27","author":"S Appukkuttan","year":"2024","unstructured":"Appukkuttan S, Yao J, Partridge J, Kong SX, Parkin J, Freedland SJ (2024) Adverse events and costs among non-metastatic castration-resistant prostate cancer patients. J Med Econ 27:145\u2013152. https:\/\/doi.org\/10.1080\/13696998.2023.2299179","journal-title":"J Med Econ"},{"key":"6597_CR2","doi-asserted-by":"publisher","first-page":"e258751","DOI":"10.1001\/jamanetworkopen.2025.8751","volume":"8","author":"AA Azad","year":"2025","unstructured":"Azad AA, Petrylak DP, Iguchi T, Shore ND, Villers A, Gomez-Veiga F et al (2025) Enzalutamide and prostate-specific antigen levels in metastatic prostate cancer: a secondary analysis of the ARCHES randomized clinical trial. JAMA Netw Open 8:e258751. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.8751","journal-title":"JAMA Netw Open"},{"key":"6597_CR3","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07627-y","author":"Z Belabaci","year":"2025","unstructured":"Belabaci Z, Brignoli G, Zilli T, Gruji\u0107 M, Mohamad I, Al-Ibraheem A et al (2025) Therapeutic outcomes of \u00b2\u00b2\u2075Ac\/\u00b9\u2077\u2077Lu-PSMA combination therapy in advanced metastatic Castration-Resistant prostate cancer: A systematic review and meta-analysis. Eur J Nucl Med Mol https:\/\/doi.org\/10.1007\/s00259-025-07627-y","journal-title":"Eur J Nucl Med Mol"},{"key":"6597_CR4","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1007\/s12325-019-01157-4","volume":"37","author":"S Chowdhury","year":"2020","unstructured":"Chowdhury S, Oudard S, Uemura H, Joniau S, Pilon D, Lefebvre P et al (2020) Matching-adjusted indirect comparison of health-related quality of life and adverse events of apalutamide versus enzalutamide in non-metastatic castration-resistant prostate cancer. Adv Ther 37:512\u2013526. https:\/\/doi.org\/10.1007\/s12325-019-01157-4","journal-title":"Adv Ther"},{"key":"6597_CR5","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11523-024-01117","volume":"20","author":"C Ciccarese","year":"2025","unstructured":"Ciccarese C, Bauckneht M, Zagaria L, Fornarini G, Beccia V, Lanfranchi F et al (2025) Defining the position of [177Lu]Lu-PSMA radioligand therapy in the treatment landscape of metastatic castration-resistant prostate cancer: a meta-analysis of clinical trials. Target Oncol 20:103\u2013112. https:\/\/doi.org\/10.1007\/s11523-024-01117","journal-title":"Target Oncol"},{"key":"6597_CR6","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.euo.2024.09.013","volume":"8","author":"NW Clarke","year":"2025","unstructured":"Clarke NW, Armstrong AJ, Oya M, Shore N, Procopio G, Daniel Guedes J et al (2025) Efficacy and safety of olaparib plus abiraterone versus placebo plus abiraterone in the first-line treatment of patients with asymptomatic\/mildly symptomatic and symptomatic metastatic castration-resistant prostate cancer: analyses from the phase 3 PROpel trial. Eur. Urol Oncol 8:394\u2013406. https:\/\/doi.org\/10.1016\/j.euo.2024.09.013","journal-title":"Eur Urol Oncol"},{"key":"6597_CR7","doi-asserted-by":"publisher","first-page":"4267","DOI":"10.1200\/JCO.23.00433","volume":"41","author":"C Dai","year":"2023","unstructured":"Dai C, Dehm SM, Sharifi N (2023) Targeting the androgen signaling axis in prostate cancer. J Clin Oncol 41:4267\u20134278. https:\/\/doi.org\/10.1200\/JCO.23.00433","journal-title":"J Clin Oncol"},{"key":"6597_CR8","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","volume":"382","author":"J de Bono","year":"2020","unstructured":"de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S et al (2020) Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med 382:2091\u20132102. https:\/\/doi.org\/10.1056\/NEJMoa1911440","journal-title":"N Engl J Med"},{"key":"6597_CR9","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S1470-2045(25)00009-9","volume":"26","author":"L Emmett","year":"2025","unstructured":"Emmett L, Subramaniam S, Crumbaker M, Joshua AM, Sandhu S, Nguyen A et al (2025) Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol 26:291\u2013299. https:\/\/doi.org\/10.1016\/S1470-2045(25)00009-9","journal-title":"Lancet Oncol"},{"key":"6597_CR10","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1093\/jnci\/djae155","volume":"116","author":"KS Faraj","year":"2024","unstructured":"Faraj KS, Oerline M, Kaufman SR, Dall C, Srivastava A, Caram MEV et al (2024) Adverse events in men with advanced prostate cancer treated with androgen biosynthesis inhibitors and androgen receptor inhibitors. J Natl Cancer Inst 116:1817\u20131824. https:\/\/doi.org\/10.1093\/jnci\/djae155","journal-title":"J Natl Cancer Inst"},{"key":"6597_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07634-z","author":"R Fern\u00e1ndez","year":"2025","unstructured":"Fern\u00e1ndez R, Soza-Ried C, Kramer V, Krieger K, M\u00fcller C, Qin Y et al (2025) Safety and efficacy of [177Lu]Lu-SibuDAB in patients with progressive metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging Adv online publication. https:\/\/doi.org\/10.1007\/s00259-025-07634-z","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6597_CR12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.eururo.2024.09.008","volume":"87","author":"E Francini","year":"2025","unstructured":"Francini E, Agarwal N, Castro E, Cheng HH, Chi KN, Clarke N et al (2025) Intensification Approaches and Treatment Sequencing in Metastatic Castration-resistant Prostate Cancer: A Systematic Review. Eur Urol 87:29\u201346. https:\/\/doi.org\/10.1016\/j.eururo.2024.09.008","journal-title":"Eur Urol"},{"key":"6597_CR13","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","volume":"389","author":"SJ Freedland","year":"2023","unstructured":"Freedland SJ, de Almeida Luz M, De Giorgi U, Gleave M, Gotto GT, Pieczonka CM et al (2023) Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer. N Engl J Med 389:1453\u20131465. https:\/\/doi.org\/10.1056\/NEJMoa2303974","journal-title":"N Engl J Med"},{"key":"6597_CR14","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1200\/JCO-25-00007","volume":"43","author":"R Garje","year":"2025","unstructured":"Garje R, Riaz IB, Naqvi SAA, Rumble RB, Taplin ME, Kungel TM et al (2025) Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update. J Clin Oncol 43:2311\u20132334. https:\/\/doi.org\/10.1200\/JCO-25-00007","journal-title":"J Clin Oncol"},{"key":"6597_CR15","doi-asserted-by":"publisher","first-page":"108459","DOI":"10.1016\/j.compbiolchem.2025.108459","volume":"118","author":"R Golla","year":"2025","unstructured":"Golla R, Jaiswal S, Jayan A, Cheemanapalli S (2025) Transcriptomic analysis of human castration-resistant prostate cancer: Insights into novel therapeutic strategies. Comput Biol Chem 118:108459. https:\/\/doi.org\/10.1016\/j.compbiolchem.2025.108459","journal-title":"Comput Biol Chem"},{"key":"6597_CR16","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s11864-025-01323-7","volume":"26","author":"K Grewal","year":"2025","unstructured":"Grewal K, Dorff TB, Mukhida SS, Agarwal N, Hahn AW (2025) Advances in Targeted Therapy for Metastatic Prostate Cancer. Curr Treat Options Oncol 26:465\u2013475. https:\/\/doi.org\/10.1007\/s11864-025-01323-7","journal-title":"Curr Treat Options Oncol"},{"key":"6597_CR17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-01553","author":"AU Kishan","year":"2025","unstructured":"Kishan AU, Valle LF, Wilhalme H, Felix C, Nabong R, Juarez-Casillas JE et al (2025) 177Lu-prostate-specific membrane antigen neoadjuvant to stereotactic ablative radiotherapy for oligorecurrent prostate cancer (LUNAR): an open-label, randomized, controlled, phase II study. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO-25-01553","journal-title":"J Clin Oncol"},{"key":"6597_CR18","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1093\/jnci\/djac081","volume":"114","author":"LY Lai","year":"2022","unstructured":"Lai LY, Oerline MK, Caram MEV, Tsao PA, Kaufman SR, Hollenbeck BK et al (2022) Risk of metabolic and cardiovascular adverse events with abiraterone or enzalutamide among men with advanced prostate cancer. J Natl Cancer Inst 114:1127\u20131134. https:\/\/doi.org\/10.1093\/jnci\/djac081","journal-title":"J Natl Cancer Inst"},{"key":"6597_CR19","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41391-024-00886-0","volume":"28","author":"A Matsukawa","year":"2025","unstructured":"Matsukawa A, Yanagisawa T, Parizi MK, Laukhtina E, Klemm J, Fazekas T et al (2025) Cardiovascular events among men with prostate cancer treated with androgen receptor signaling inhibitors: a systematic review, meta-analysis, and network meta-analysis. Prostate Cancer Prostatic Dis 28:298\u2013308. https:\/\/doi.org\/10.1038\/s41391-024-00886-0","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"6597_CR20","doi-asserted-by":"publisher","first-page":"3610","DOI":"10.1158\/1078-0432.CCR-20-4616","volume":"27","author":"RR McKay","year":"2021","unstructured":"McKay RR, Kwak L, Crowdis JP, Sperger JM, Zhao SG, Xie W et al (2021) Phase II multicenter study of enzalutamide in metastatic castration-resistant prostate cancer to identify mechanisms driving resistance. Clin Cancer Res 27:3610\u20133619. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-4616","journal-title":"Clin Cancer Res"},{"key":"6597_CR21","doi-asserted-by":"publisher","first-page":"3386","DOI":"10.7150\/thno.106574","volume":"15","author":"G Ninatti","year":"2025","unstructured":"Ninatti G, Scilipoti P, Pini C, Barletta F, Longoni M, Gelardi F et al (2025) Time for action: actinium-225 PSMA-targeted alpha therapy for metastatic prostate cancer - a systematic review and meta-analysis. Theranostics 15:3386\u20133399. https:\/\/doi.org\/10.7150\/thno.106574","journal-title":"Theranostics"},{"key":"6597_CR22","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ejca.2022.04.016","volume":"170","author":"G Roubaud","year":"2022","unstructured":"Roubaud G, \u00d6zg\u00fcro\u011flu M, Penel N, Matsubara N, Mehra N, Kolinsky MP et al (2022) Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: further analyses from the PROfound study. Eur J Cancer 170:73\u201384. https:\/\/doi.org\/10.1016\/j.ejca.2022.04.016","journal-title":"Eur J Cancer"},{"key":"6597_CR23","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s11523-025-01146-4","volume":"20","author":"F Saad","year":"2025","unstructured":"Saad F, Armstrong AJ, Oya M, George DJ, Sugimoto M, McKay RR et al (2025) Olaparib monotherapy or in combination with abiraterone for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and a BRCA mutation. Target Oncol 20:445\u2013466. https:\/\/doi.org\/10.1007\/s11523-025-01146-4","journal-title":"Target Oncol"},{"key":"6597_CR24","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1016\/j.euo.2024.03.006","volume":"7","author":"F Saad","year":"2024","unstructured":"Saad F, Armstrong AJ, Oya M, Vianna K, \u00d6zg\u00fcro\u011flu M, Gedye C et al (2024) Tolerability of olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: further results from the phase 3 PROpel trial. Eur Urol Oncol 7:1394\u20131402. https:\/\/doi.org\/10.1016\/j.euo.2024.03.006","journal-title":"Eur Urol Oncol"},{"key":"6597_CR25","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K et al (2021) Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med 385:1091\u20131103. https:\/\/doi.org\/10.1056\/NEJMoa2107322","journal-title":"N Engl J Med"},{"key":"6597_CR26","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1016\/j.ccell.2024.10.015","volume":"42","author":"G Seed","year":"2024","unstructured":"Seed G, Beije N, Yuan W, Bertan C, Goodall J, Lundberg A et al (2024) Elucidating acquired PARP inhibitor resistance in advanced prostate cancer. Cancer Cell 42:2113\u20132123e4. https:\/\/doi.org\/10.1016\/j.ccell.2024.10.015","journal-title":"Cancer Cell"},{"key":"6597_CR27","doi-asserted-by":"publisher","first-page":"116110","DOI":"10.1016\/j.ejca.2025.116110","volume":"232","author":"ND Shore","year":"2025","unstructured":"Shore ND, De Giorgi U, Kalac M, Tang Y, Croitoru R, Rosales M et al (2025) Enzalutamide with or without leuprolide in patients with high-risk biochemically recurrent prostate cancer: EMBARK post hoc analysis by age. Eur J Cancer 232:116110. https:\/\/doi.org\/10.1016\/j.ejca.2025.116110","journal-title":"Eur J Cancer"},{"key":"6597_CR28","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11912-021-01042-w","volume":"23","author":"M Sun","year":"2021","unstructured":"Sun M, Niaz MJ, Niaz MO, Tagawa ST (2021) Prostate-specific membrane antigen (PSMA)-targeted radionuclide therapies for prostate cancer. Curr Oncol Rep 23:59. https:\/\/doi.org\/10.1007\/s11912-021-01042-w","journal-title":"Curr Oncol Rep"},{"key":"6597_CR29","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1093\/jjco\/hyae098","volume":"54","author":"F Urabe","year":"2024","unstructured":"Urabe F, Imai Y, Goto Y, Tashiro K, Hashimoto M, Yoshihara K et al (2024) Real-world evidence of triplet therapy efficacy in patients with metastatic castration-sensitive prostate cancer: a Japanese multicenter study. Jpn J Clin Oncol 54:1208\u20131213. https:\/\/doi.org\/10.1093\/jjco\/hyae098","journal-title":"Jpn J Clin Oncol"},{"key":"6597_CR30","doi-asserted-by":"publisher","first-page":"451","DOI":"10.18433\/jpps31003","volume":"23","author":"X Wang","year":"2020","unstructured":"Wang X, Hui Y, Wang S, Hu X, Yu X, Wang W et al (2020) Comparison of effectiveness and safety outcomes of abiraterone versus enzalutamide in patients with metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. J Pharm Pharm Sci 23:451\u2013461. https:\/\/doi.org\/10.18433\/jpps31003","journal-title":"J Pharm Pharm Sci"},{"key":"6597_CR31","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1146\/annurev-pharmtox-052220-015912","volume":"62","author":"D Westaby","year":"2022","unstructured":"Westaby D, de La Maza F, Paschalis MLD, Jimenez-Vacas A, Welti JM, de Bono J, J., et al (2022) A new old target: androgen receptor signaling and advanced prostate cancer. Annu Rev Pharmacol Toxicol 62:131\u2013153. https:\/\/doi.org\/10.1146\/annurev-pharmtox-052220-015912","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"6597_CR32","doi-asserted-by":"publisher","first-page":"25712","DOI":"10.1038\/s41598-024-77889-3","volume":"14","author":"S Wu","year":"2024","unstructured":"Wu S, Hu W, Chen M, Xiao X, Liu R (2024) A real-world pharmacovigilance study of FDA adverse event reporting system events for Lutetium-177-PSMA-617. Sci Rep 14:25712. https:\/\/doi.org\/10.1038\/s41598-024-77889-3","journal-title":"Sci Rep"},{"key":"6597_CR33","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.urolonc.2018.05.008","volume":"36","author":"SS Yadav","year":"2018","unstructured":"Yadav SS, Stockert JA, Hackert V, Yadav KK, Tewari AK (2018) Intratumor heterogeneity in prostate cancer. Urol Oncol 36:349\u2013360. https:\/\/doi.org\/10.1016\/j.urolonc.2018.05.008","journal-title":"Urol Oncol"},{"key":"6597_CR34","doi-asserted-by":"publisher","first-page":"104376","DOI":"10.1016\/j.critrevonc.2024.104376","volume":"198","author":"SC Yazgan","year":"2024","unstructured":"Yazgan SC, Akkus E, Yekeduz E, Urun Y (2024) Thromboembolic risk in prostate cancer patients treated with PARP inhibitors: A systematic review and meta-analysis. Crit Rev Oncol Hematol 198:104376. https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104376","journal-title":"Crit Rev Oncol Hematol"},{"key":"6597_CR35","doi-asserted-by":"publisher","first-page":"2880","DOI":"10.7150\/ijbs.109638","volume":"21","author":"Z Zhao","year":"2025","unstructured":"Zhao Z, Jing Y, Xu Z, Zhao H, He X, Lu T et al (2025) The mechanism of histone modifications in regulating enzalutamide sensitivity in advanced prostate cancer. Int J Biol Sci 21:2880\u20132890. https:\/\/doi.org\/10.7150\/ijbs.109638","journal-title":"Int J Biol Sci"},{"key":"6597_CR36","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07682-5","author":"F Rosar","year":"2025","unstructured":"Rosar F, Khreish F, Burgard C, Fursov A, Blickle A, Bartholom\u00e4 M et al (2025) Comparison of mCRPC [177Lu]-PSMA-617 radioligand therapy with and without concurrent enzalutamide medication in a real-world setting. Eur J Nucl Med Mol https:\/\/doi.org\/10.1007\/s00259-025-07682-5","journal-title":"Eur J Nucl Med Mol"},{"key":"6597_CR37","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.euo.2024.11.011","volume":"8","author":"F Zacchi","year":"2025","unstructured":"Zacchi F, Abida W, Antonarakis ES, Bryce AH, Castro E, Cheng HH et al (2025) Recent and future developments in the use of poly (ADP-ribose) Polymerase inhibitors for prostate cancer. Eur Urol Oncol 8:818\u2013828. https:\/\/doi.org\/10.1016\/j.euo.2024.11.011","journal-title":"Eur Urol Oncol"},{"key":"6597_CR38","doi-asserted-by":"publisher","first-page":"101917","DOI":"10.1016\/j.adro.2025.101917","volume":"11","author":"AY Zhang","year":"2025","unstructured":"Zhang AY, Bertsch H, Chaudhary A, Salner A (2025) Lutetium 177Lu Vipivotide tetraxetan efficacy and toxicity in advanced prostate cancer. Adv Radiat Oncol 11:101917. https:\/\/doi.org\/10.1016\/j.adro.2025.101917","journal-title":"Adv Radiat Oncol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06597-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-026-06597-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06597-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T08:25:49Z","timestamp":1784017549000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-026-06597-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,14]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6597"],"URL":"https:\/\/doi.org\/10.1007\/s00345-026-06597-6","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,14]]},"assertion":[{"value":"20 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This is a retrospective observational study based entirely on data from the publicly available and fully de-identified U.S. Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database. In accordance with institutional and national guidelines, research utilizing such anonymized public data is exempt from ethics committee review.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}],"article-number":"497"}}